Effect of non-ergot dopamine agonists on health-related quality of life of patients with restless legs syndrome

Annals of Pharmacotherapy

Volumn 43, Issue 5, 2009, Pages 813-821

  Talati, Ripple ^a   Phung, Olivia J ^a   Mather, Jeffrey ^a   Coleman, Craig I ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Health related quality of life; Non ergot dopamine agonist; Restless legs syndrome

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFECT; HUMAN; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RESTLESS LEGS SYNDROME; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ATTITUDE TO HEALTH; DOPAMINE AGONISTS; HUMANS; PUBLICATION BIAS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESTLESS LEGS SYNDROME; SENSITIVITY AND SPECIFICITY;

EID: 65749092232     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L673     Document Type: Article

References (23)

1. Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:560-583 (Pubitemid 44138822)
2. Siber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004;79:916-922 (Pubitemid 38879959)
3. Baker WL, White CM, Coleman CI. Effect of nonergot dopamine agonists on symptoms of restless legs syndrome. Ann Fam Med 2008;6:253-262
4. Quilici S, Abrams KR, Nicolas A, et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med 2008;9:715-726
5. Abetz L, Vallow SM, Kirsch J, Allen RP, Washburn T, Earley CJ. Validation of the Restless Legs Syndrome Quality of Life Questionnaire. Value Health 2005;8:157-167 (Pubitemid 40525377)
6. Abetz L, Arbuckle R, Allen RP, Mavraki E, Kirsch J. The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life Questionnaire (RLSQoL) in a trial population. Health Qual Life Outcomes 2005;3:79. DOI 10.1186/1477-7525-3-79 (Pubitemid 41800240)
7. Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604.
8. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.0.0 [updated February 2008]. Cochrane Collaboration, 2008. www.cochrane-handbook.org (accessed 2008 Jul 22).
9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
10. Efficace F, Bottomley A, Osoba D, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials: does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 2003;21:3502-3511
11. Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 2008;44:1497-1506
12. Cohen J. Statistical power analysis in the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc., 1988.
13. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634 (Pubitemid 27387172)
14. Oertel WH, Benes H, Garcia-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled six-week dose-finding trial in Europe. Sleep Med 2008;9:228-239
15. Bogan RK, Fry JM, Schmidt M, Carson SW, Ritchie SY. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006;81:17-27. (Pubitemid 43054313)
16. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006;67:1034-1039
17. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004;27:907-914
18. Trenkwalder C, Borreguero-Garcia D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004:75:92-97
19. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, paralled-group, placebo-controlled study. Mov Disord 2004;19:1414-1423
20. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 2006;21:1627-1635
21. Trenkwalder C, Kolster-Stiasny K, Kupsch A, Oertel WH, Koester J, Reess J. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord 2006;21:1404-1410 (Pubitemid 44613292)
22. Kohnen R, Benes H, Heinrich CR, Kurella B. Development of the disease-specific restless legs syndrome quality of life (RLS-QoL) questionnaire. Mov Disord 2002;17(suppl 5):P743.
23. Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain 2008;131:902-917